Skip to main content
. Author manuscript; available in PMC: 2020 Jan 15.
Published in final edited form as: Bioorg Med Chem Lett. 2018 Nov 28;29(2):204–211. doi: 10.1016/j.bmcl.2018.11.055

Figure 5. C17 causes the accumulation of HMW-Ub and reduce the levels of Bcr-Abl in K562 cells.

Figure 5.

A. The accumulation of K48-linked Ub in K562 leukemia cells treated with diphenyl carbonates (50 μM) for 2 h. B. As in A, but Bcr-Abl was measured by immunoblotting with anti-Abl antibodies. C. Dose dependence of the C17-induced depletion of Bcr-Abl. Intervening lane removed for clarity. D. Quantification of blots as in C. E. K562 cells were treated with C17 (50 μM) in the presence and absence of bortezomib (6 μM) for 4 h and Bcr-Abl was measured by immunoblotting with anti-Abl antibodies. F. Quantitation of blot in E. Significance: DMSO relative to C17 and bortezomib p=0.002; DMSO relative to C17, p = 0.03. G. Effect of C17 on the cell cycle as determined by FACS. Black bars represent apoptotic cells (sub G1) and grey bars show cells in G1.